Randomized Controlled Trial
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2014; 20(31): 11012-11018
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.11012
Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury
Chen Huang, Bin Lu, Yi-Hong Fan, Lu Zhang, Ning Jiang, Shuo Zhang, Li-Na Meng
Chen Huang, Bin Lu, Yi-Hong Fan, Lu Zhang, Ning Jiang, Shuo Zhang, Li-Na Meng, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China
Author contributions: Lu B designed and supervised the study; Huang C performed the majority of the survey and interpreted the data as well as wrote the manuscript; Fan YH, Zhang L, Jiang N, Zhang S analyzed the video; Meng LN performed the organization and management of volunteers; all authors have read and approved the final version to be published.
Supported by Medical and Health Scientific Research Foundation of Zhejiang Province, China, No. 20112DA022
Correspondence to: Bin Lu, MD, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. lvbin@medmail.com.cn
Telephone: +86-571-87032028 Fax: +86-571-87077785
Received: December 23, 2013
Revised: February 16, 2014
Accepted: April 30, 2014
Published online: August 21, 2014
Processing time: 249 Days and 18.9 Hours
Abstract

AIM: To evaluate the effect of muscovite in preventing small bowel injury induced by nonsteroidal anti-inflammatory drugs (NSAIDs).

METHODS: We recruited and screened thirty-two healthy volunteers who were randomly allocated equally into two groups: an NSAID control group, who received 75 mg slow-release diclofenac, twice daily for 14 d; and an NSAID-muscovite group, who received 3 g of muscovite in addition to the 75 mg of slow-release diclofenac, twice daily for 14 d. For gastroprotection, both groups were administered 20 mg/d of the proton pump inhibitor omeprazole. All eligible subjects underwent video capsule endoscopy (CE) prior to and 14 d after treatment.

RESULTS: Thirty subjects (NSAID-muscovite group, n =16; NSAID control group, n =14) finally completed the whole trail. At the baseline CE examination, no statistically significant differences between the two groups have been observed. However, after 14 d of drug treatment, a significant difference was observed in the percentage of subjects with mucosal breaks when comparing the NSAID-muscovite group with the NSAID control group. While 71.4% (10/14) of subjects in the NSAID control group had at least one mucosal break, co-administration of muscovite in the NSAID-muscovite group reduced the rate to 31.3% (5/16) (P = 0.028). Moreover, higher number of mucosal breaks was found in the NSAID control group vs that in the NSAID-muscovite group (P < 0.05).

CONCLUSION: Muscovite co-therapy reduced the incidence of small intestinal injury after 14 d of diclofenac administration.

Keywords: Muscovite; Nonsteroidal anti-inflammatory drugs; Small intestinal injury; Video capsule endoscopy

Core tip: This is a randomized, open-label, controlled clinical trial to evaluate the incidence of small bowel damage by capsule endoscopy in healthy participants who received treatment with the nonsteroidal anti-inflammatory drug (NSAID) diclofenac and the effect of muscovite in preventing NSAID-induced small bowel injury.